PMID- 28287043
OWN - NLM
STAT- MEDLINE
DCOM- 20180411
LR  - 20220114
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 20
IP  - 7
DP  - 2017 Jul
TI  - Healthcare and economic burden of adverse events among patients with chronic 
      myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
PG  - 687-691
LID - 10.1080/13696998.2017.1302947 [doi]
AB  - OBJECTIVES: BCR-ABL1 tyrosine kinase inhibitors (TKIs) are established treatments 
      for chronic myelogenous leukemia (CML); however, they are associated with 
      infrequent, but clinically serious adverse events (AEs). The objective of this 
      analysis was to assess healthcare resource utilization and costs associated with 
      AEs, previously identified using the FDA Adverse Event Reporting System (FAERS) 
      in another study, among TKI-treated patients. METHODS: Adult patients with >/=1 
      inpatient or >/=2 outpatient ICD-9-CM diagnosis codes for CML and >/=1 claim for a 
      TKI treatment between January 1, 2006 and September 30, 2012 were identified from 
      the Commercial and Medicare MarketScan databases. The first claim for a TKI was 
      designated as the index event. Patients were required to have no TKI treatment 
      during a 12-month baseline period. Healthcare resource utilization and costs 
      associated with select AEs having the strongest association with TKI treatment 
      (femoral arterial stenosis [FAS], peripheral arterial occlusive disease [PAOD], 
      intermittent claudication, coronary artery stenosis [CAS], pericardial effusion, 
      pleural effusion, malignant pleural effusion, conjunctival hemorrhage) were 
      evaluated during a 12-month follow-up period. RESULTS: The study sample included 
      2,005 CML patients receiving TKI therapy (mean age = 56 years; 56% male). Among 
      all evaluated AEs, the highest mean inpatient healthcare costs were observed for 
      FAS ($16,800 per patient) and PAOD ($14,263 per patient), which had total mean 
      medical costs (inpatient + outpatient) of $17,015 and $15,154 per patient, 
      respectively. Mean outpatient healthcare costs were highest for CAS ($1,861 per 
      patient), followed by intermittent claudication ($947 per patient), PAOD ($891 
      per patient), and pleural effusion ($890 per patient). Total mean medical costs 
      for fluid retention-related AEs, including pericardial effusion and pleural 
      effusion, were $2,797 and $1,908 per patient, respectively. CONCLUSIONS: The 
      healthcare costs of AEs identified in the FAERS as having the strongest 
      association with TKI treatment are substantial. Vascular stenosis-related AEs, 
      including FAS and PAOD, have the highest cost burden.
FAU - Lin, Jay
AU  - Lin J
AD  - a Novosys Health , Green Brook , NJ , USA.
FAU - Makenbaeva, Dinara
AU  - Makenbaeva D
AD  - b Bristol-Myers Squibb , Princeton , NJ , USA.
FAU - Lingohr-Smith, Melissa
AU  - Lingohr-Smith M
AD  - a Novosys Health , Green Brook , NJ , USA.
FAU - Bilmes, Robyn
AU  - Bilmes R
AD  - b Bristol-Myers Squibb , Princeton , NJ , USA.
LA  - eng
PT  - Journal Article
DEP - 20170312
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - F41401512X (nilotinib)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects/*economics/therapeutic use
MH  - Dasatinib/adverse effects/economics
MH  - Female
MH  - Health Services/economics/statistics & numerical data
MH  - Humans
MH  - Imatinib Mesylate/adverse effects/economics
MH  - Insurance Claim Review
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Models, Economic
MH  - Pleural Effusion/chemically induced/economics
MH  - Protein Kinase Inhibitors/*adverse effects/*economics/therapeutic use
MH  - Pyrimidines/adverse effects/economics
MH  - Retrospective Studies
MH  - Vascular Diseases/chemically induced/economics
MH  - Young Adult
OTO - NOTNLM
OT  - Adverse events
OT  - Chronic myelogenous leukemia
OT  - Cost
OT  - Healthcare
OT  - Tyrosine kinase inhibitors
EDAT- 2017/03/14 06:00
MHDA- 2018/04/12 06:00
CRDT- 2017/03/14 06:00
PHST- 2017/03/14 06:00 [pubmed]
PHST- 2018/04/12 06:00 [medline]
PHST- 2017/03/14 06:00 [entrez]
AID - 10.1080/13696998.2017.1302947 [doi]
PST - ppublish
SO  - J Med Econ. 2017 Jul;20(7):687-691. doi: 10.1080/13696998.2017.1302947. Epub 2017 
      Mar 12.